Company intelligence / Profile preview
ExSAR
Monmouth Junction, New Jersey, United Stateslinkedin.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
ExSAR developed an automated hydrogen/deuterium exchange mass spectrometry platform to rapidly map drug-target interactions. The company advanced small molecule repurposing candidates into early clinical trials for rare diseases such as Type I Gaucher disease and chronic GM2 gangliosidosis. Clinical trials were suspended or withdrawn, and the company is now out of business with no ongoing pipeline activity.
- Therapeutic areas
- Rare DiseasesNeurology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Beyond the preview
Go deeper on ExSAR.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ExSAR.